Apatinib Degrades PD-L1 and Reconstitutes Colon Cancer Microenvironment via the Regulation of Myoferlin
These findings highlight novel antitumor mechanisms of MYOF and suggest that combining apatinib with ICB therapy may improve CRC treatment outcomes, offering a promising strategy to enhance immune responses.
Authors
- Chunyi Gao
- Lingying Zhao
- Yongcheng Su (ORCID: https://orcid.org/0000-0001-6322-7681)
- Miaomiao Ma (ORCID: https://orcid.org/0000-0001-8115-4148)
- Beibei Xu (ORCID: https://orcid.org/0000-0003-3507-9321)
- Xiao Li (ORCID: https://orcid.org/0000-0002-8889-9609)
- Wenqing Zhang (ORCID: https://orcid.org/0000-0003-1604-7471)
- Lu Chen (ORCID: https://orcid.org/0000-0002-5775-6947)
- Xiaoting Hong (ORCID: https://orcid.org/0000-0002-0787-4136)
- Tianhui Hu (ORCID: https://orcid.org/0000-0003-3998-5145)
Institutions
- Xiamen University (CN)
- Chinese Academy of Sciences (CN)
- Gannan Medical University (CN)
- Zhongshan Hospital of Xiamen University (CN)
- Shenzhen Institutes of Advanced Technology (CN)
- Shenzhen Children's Hospital (CN)
Publication Details
- Journal
- Cancers
- Published
- 2025-02-05
- DOI
- https://doi.org/10.3390/cancers17030524
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Gannan Medical University